Oral & Salivary Cancer Biology Program

The Oral and Salivary Cancer Biology Program supports basic and translational research to improve detection and treatment of cancers of the Oral Cavity, Pharynx, and Salivary Glands. Basic research focuses on susceptibilities and mechanisms that influence tumor initiation, promotion, and progression. Translational research focuses on development of innovative biomarkers, novel diagnostic technologies, and appropriate human specimens to better characterize cancers and improve medical decision making and treatment response evaluation.

Staff Contacts

Funding Opportunity Announcements

Title Staff Contact Opportunity Number Activity Code Expiration Date
Advancing Cancer Immunotherapy by Mitigating Immune-related Adverse Events (irAEs) (U01 Clinical Trial Not Allowed) RFA-CA-19-044 U01
Administrative Supplement for Research on Bioethical Issues PA-19-217 C06, D43, D71
Successor-in-Interest (Type 6 Parent) PA-16-286 C06, D43, D71
NIDCR Small Grant Program for New Investigators (R03) PAR-16-409 R03
Factors Underlying Differences in Female and Male Presentation for Dental, Oral, and Craniofacial Diseases and Conditions (R01) PA-16-295 R01
Factors Underlying Differences in Female and Male Presentation for Dental, Oral, and Craniofacial Diseases and Conditions (R21) PA-16-296 R21
Academic-Industrial Partnerships to Translate and Validate in vivo Cancer Imaging Systems (R01 Clinical Trial Optional) PAR-18-009 R01
Development of Highly Innovative Tools and Technology for Analysis of Single Cells (STTR) (R41/R42) PA-17-148 R41, R42
Development of Highly Innovative Tools and Technology for Analysis of Single Cells (SBIR) (R43/R44) PA-17-147 R43, R44
Administrative Supplements for Research on Dietary Supplements (Admin Supp) PA-18-817 P30, P40, P50
Secondary Analysis and Integration of Existing Data to Elucidate the Genetic Architecture of Cancer Risk and Related Outcomes (R21) PAR-17-243 R21
Secondary Analysis and Integration of Existing Data to Elucidate the Genetic Architecture of Cancer Risk and Related Outcomes (R01) PA-17-239 R01
Electronic Nicotine Delivery Systems (ENDS): Population, Clinical and Applied Prevention Research (R21 - Clinical Trial Optional) PAR-18-848 R21
Electronic Nicotine Delivery Systems (ENDS): Basic Mechanisms of Health Effects (R21 - Clinical Trial Not Allowed) PAR-17-475 R21
Electronic Nicotine Delivery Systems (ENDS): Basic Mechanisms of Health Effects (R01 - Clinical Trial Not Allowed) PAR-18-845 R01
Electronic Nicotine Delivery Systems (ENDS): Basic Mechanisms of Health Effects (R01 - Clinical Trial Not Allowed) PAR-17-476 R01
Electronic Nicotine Delivery Systems (ENDS): Basic Mechanisms of Health Effects (R21 - Clinical Trial Not Allowed) PAR-18-846 R01
NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed) PA-18-484 R01
NIH Support for Conferences and Scientific Meetings (Parent R13 Clinical Trial Not Allowed) PA-18-648 R13
Biology of Lung, and Head and Neck Preneoplasias (R01- Clinical Trial Not Allowed) PA-17-459 R01
Academic Research Enhancement Award (Parent R15 Clinical Trial Not Allowed) PA-18-504 R15
Biology of Lung, and Head and Neck Preneoplasias (R21 - Clinical Trial Not Allowed) 17-460 R21
Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Optional) PAR-18-530 R01
Specialized Programs of Research Excellence (SPOREs) in Human Cancers for years 2018, 2019 and 2020 (P50) PAR-18-313 P50
Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional) PA-18-591 C06, D43, D71
Change of Grantee Organization (Type 7 Parent) PA-18-590 C06, D43, D71
Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional) PA-18-591 C06, D43, D71
Age-related Microbiota Changes and their Implications in Chronic Disease Prevention, Treatment and Progression (R01 Clinical Trial Optional) PA-18-738 R01
Age-related Microbiota Changes and their Implications in Chronic Disease Prevention, Treatment and Progression (R21 Clinical Trial Optional) PA-18-739 R21
Administrative Supplements to Promote Diversity in Small Businesses-SBIR/STTR (Admin Supp Clinical Trial Not Allowed) PA-18-837 R41, R42, R43
Precision Imaging of Oral Lesions (R21-Clinical Trial Not Allowed) PAR-18-788 D71, R21
Research Supplements to Promote Diversity in Health-Related Research (Admin Supp - Clinical Trial Not Allowed) PA-18-906 C06, D43, D71
Precision Imaging of Oral Lesions (R01- Clinical Trial Not Allowed) PAR-18-787 R01
NIH Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required) PA-19-091 R01
NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required) PA-19-092 R21
NIH Administrative Supplements to Recover Losses Due to Hurricanes Harvey, Irma, and Maria Under the Bipartisan Budget Act of 2018 Non-Construction (Admin Supp Clinical Trial Optional) PA-18-936 D43, D71, DP1
Research Enhancement Award Program (REAP) for Health Professional Schools and Graduate Schools (R15 Clinical Trial Not Allowed) PAR-19-134 R15
Achieving Tissue Robustness Through Harnessing Immune System Plasticity (R01 Clinical Trial Not Allowed) PAR-19-172 R01
Achieving Tissue Robustness Through Harnessing Immune System Plasticity (R21 Clinical Trial Not Allowed) PAR-19-173 R21